Predictive Factors for Peritoneal Metastases in Colorectal Cancer: A Retrospective Study Conducted at a Tertiary Care Center in Riyadh, Saudi Arabia

沙特阿拉伯利雅得一家三级医疗中心开展的回顾性研究:结直肠癌腹膜转移的预测因素

阅读:1

Abstract

Background The incidence of colorectal cancer (CRC) is increasing nationally, emphasizing the importance of early detection. Late-stage diagnosis, particularly with peritoneal metastasis (PM), is associated with poor outcomes despite advancements in treatment. PM poses a challenge owing to the lack of standardized treatment, although cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) shows promise in improving survival rates. This study aimed to document the incidence and risk factors for patients presenting with PM following CRC. Materials and methods This retrospective chart review study was conducted at King Abdulaziz Medical City in Saudi Arabia. Patients of all ages and genders who underwent surgical resection for CRC from January 2016 to December 2021 were included. Patients with PM at primary index surgery, distant organ metastasis to the lung or liver, or other types of cancer were excluded. The data was analyzed via SPSS Statistics version 27.0 (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.), t-test, Wilcoxon rank-sum test, chi-square test, and Fisher's exact tests. Results Among 565 patients with CRC, 65 patients (11.5%) developed PM. Tumor characteristics such as T4 stage, mucinous tumors, elevated CEA, and the presence of ovarian metastasis at primary resection were independent factors for peritoneal recurrence. However, in univariate and multivariate associations, the presence of ovarian metastasis, mucinous tumors, postoperative CEA levels exceeding 5 ng/ml, and perforation are significant risk factors for PM development post-surgery, with hazard ratios of 6.457 (CI 2.481-16.801) and 4.057 (2.029-8.115), respectively. Conclusion Mucinous tumors and ovarian metastasis are significant risk factors for PM development, emphasizing the importance of early identification for tailored treatment strategies such as CRS and HIPEC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。